Innovent Biologics (1801) Stock Overview
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 1801 from our risk checks.
1801 Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Innovent Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$102.40 |
| 52 Week High | HK$112.70 |
| 52 Week Low | HK$69.55 |
| Beta | 0.25 |
| 1 Month Change | 0% |
| 3 Month Change | 33.86% |
| 1 Year Change | 8.13% |
| 3 Year Change | 162.56% |
| 5 Year Change | 39.80% |
| Change since IPO | 517.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1801 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 5.7% | 2.0% | -0.7% |
| 1Y | 8.1% | -30.3% | -6.1% |
Return vs Industry: 1801 exceeded the Hong Kong Biotechs industry which returned -30.3% over the past year.
Return vs Market: 1801 exceeded the Hong Kong Market which returned -6.1% over the past year.
Price Volatility
| 1801 volatility | |
|---|---|
| 1801 Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 15.0% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 1801 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1801's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 8,754 | Michael Yu | www.innoventbio.com |
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection).
Innovent Biologics, Inc. Fundamentals Summary
| 1801 fundamental statistics | |
|---|---|
| Market cap | HK$178.27b |
| Earnings (TTM) | HK$1.44b |
| Revenue (TTM) | HK$18.40b |
Is 1801 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1801 income statement (TTM) | |
|---|---|
| Revenue | CN¥15.71b |
| Cost of Revenue | CN¥3.76b |
| Gross Profit | CN¥11.95b |
| Other Expenses | CN¥10.71b |
| Earnings | CN¥1.23b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.71 |
| Gross Margin | 76.06% |
| Net Profit Margin | 7.85% |
| Debt/Equity Ratio | 11.0% |
How did 1801 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 16:44 |
| End of Day Share Price | 2026/09/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innovent Biologics, Inc. is covered by 66 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shan He | Bernstein |
| Rebecca Liang | Bernstein |
| Bo Li | BofA Global Research |